Q-omics provides the consensus-scored ZNF502 profile across patient tissues and cancer cell-line models. ZNF502 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ZNF502 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, ZNF502 RNA expression shows 19,346 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, KIRC, and UVM as cancer lineages where ZNF502 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF502 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF502 survival associations across molecular data types. ZNF502 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF502 RNA expression–survival associations across cancer types. High ZNF502 expression shows unfavorable associations in MESO, but favorable associations in LUAD, KIRC, KIRP, HNSC and READ. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for ZNF502 RNA expression.
This table summarizes ZNF502 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF502. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF502 shows lower tumor expression in KIRC, UCEC, BRCA, KICH, BLCA and THCA. The KIRC box plot shows higher ZNF502 RNA expression in normal versus tumor tissue (log2 FC = −1.160, t-test p < 0.001).
This table shows molecular features associated with ZNF502 in patient tissues and cancer cell lines. In patient samples, ZNF502 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF502 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
